46-60 of 127
Where Does This Patient Land? Making Sense of Risk and LDL-C Goals
MinuteCE®Where Does This Patient Land? Making Sense of Risk and LDL-C Goals
Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Rishi Wadhera, MD, MPP, Mphil
The Dose Matters: Optimizing Statin Intensity in ASCVD Management
MinuteCE®The Dose Matters: Optimizing Statin Intensity in ASCVD Management
Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Rishi Wadhera, MD, MPP, Mphil
Expanding Access: Alternative Models for Delivering Lipid-Lowering Therapy
MinuteCE®Expanding Access: Alternative Models for Delivering Lipid-Lowering Therapy
Rishi Wadhera, MD, MPP, Mphil
Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Rishi Wadhera, MD, MPP, Mphil
Statins and Safety: What the Data Say About Dementia, Cancer, and More
MinuteCE®Statins and Safety: What the Data Say About Dementia, Cancer, and More
Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Rishi Wadhera, MD, MPP, Mphil
Closing the Loop: Practical Strategies for Timely Lipid Panel Follow-Up
MinuteCE®Closing the Loop: Practical Strategies for Timely Lipid Panel Follow-Up
Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Rishi Wadhera, MD, MPP, Mphil
- advertisement
Target in Sight: Escalating Therapy to Reach LDL-C Goals
MinuteCE®Target in Sight: Escalating Therapy to Reach LDL-C Goals
Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Rishi Wadhera, MD, MPP, Mphil
Personalizing LDL-C Treatment—Novel Options That Align With Patient Preferences
MinuteCE®Personalizing LDL-C Treatment—Novel Options That Align With Patient Preferences
Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Rishi Wadhera, MD, MPP, Mphil
Unmasking Hidden Risk: The Role of Lp(a) in Cardiovascular Risk Assessment
MinuteCE®Unmasking Hidden Risk: The Role of Lp(a) in Cardiovascular Risk Assessment
Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Rishi Wadhera, MD, MPP, Mphil
Bridging ASCVD Care Between Academic and Rural Settings
MinuteCE®Bridging ASCVD Care Between Academic and Rural Settings
Rishi Wadhera, MD, MPP, Mphil
Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Nonsteroidal MRA & SGLT2i in People With CKD & T2D: Current Evidence and Rationale for Combination Therapy
CME/CENonsteroidal MRA & SGLT2i in People With CKD & T2D: Current Evidence and Rationale for Combination Therapy
prof. Hiddo Heerspink
Jennifer B. Green, MD
Cracking the Case: A Clinical Consult on Potassium Binders in Patients with Chronic Kidney Disease and Heart Failure
CME/CECracking the Case: A Clinical Consult on Potassium Binders in Patients with Chronic Kidney Disease and Heart Failure
Pam R. Taub, MD, FACC, FASPC
Jan T. Kielstein, MD, FASN, FERA
- advertisement
Pearls of Wisdom: Optimizing Hyperkalemia Management in Patients with CKD
CME/CEPearls of Wisdom: Optimizing Hyperkalemia Management in Patients with CKD
Matthew R. Weir, MD
Nihar R. Desai, MD, MPH
Ellie Kelepouris, MD, FACP, FAHA
Renato D. Lopes, MD, MHS, PhD
Valeria Caso, MD, PhD
Alexander T. Cohen, MD, MBBS
Renato D. Lopes, MD, MHS, PhD
